0001104659-23-033407.txt : 20230316 0001104659-23-033407.hdr.sgml : 20230316 20230316180132 ACCESSION NUMBER: 0001104659-23-033407 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shustov Andrei CENTRAL INDEX KEY: 0001969686 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 23740071 MAIL ADDRESS: STREET 1: 7 PARKLAND DRIVE CITY: MILFORD STATE: NJ ZIP: 08848 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 3 1 tm239814d1_3.xml OWNERSHIP DOCUMENT X0206 3 2023-02-15 0 0001279704 Cellectar Biosciences, Inc. CLRB 0001969686 Shustov Andrei C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM NJ 07932 0 1 0 0 Senior Vice President, Medical Common Stock 7181.7 D Exhibit 24 - Power of Attorney /s/ Christina Blakley, Attorney-in-fact for Andrei Shustov 2023-03-16 EX-24 2 tm239814d1_ex24.htm EXHIBIT 24

Exhibit 24

 

CONFIRMING STATEMENT

 

This Statement confirms that the undersigned has authorized Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue and Allen Kogan, each acting singly, to prepare, execute and file on the undersigned's behalf a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the U.S. Securities and Exchange Commission (the “SEC”) of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation thereunder.

 

This Statement further confirms that the undersigned has authorized and designated Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the SEC as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc.

 

The authority of Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

 

Dated: March 13, 2023

 

Signed: /s/ Andrei Shustov

 

Print Name: Andrei Shustov, M.D.